Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?

Published on Sep 21, 2016in Journal of Oncology Practice3.551
· DOI :10.1200/JOP.2015.009191
Stephen M. Ansell99
Estimated H-index: 99
(Mayo Clinic)
Tumor-specific cytotoxic T cells have the capacity to target and eradicate malignant B cells in patients with Hodgkin and non-Hodgkin lymphoma; however, multiple mechanisms, including regulatory T cells, immunosuppressive ligands, and immune exhaustion, suppress an effective antitumor immune response. One mechanism that is used by malignant cells to inhibit the immune response is overexpression of programmed death ligand 1 or 2 (PD-L1 or PD-L2) on the cancer cell surface. These ligands interact with the programmed death-1 (PD-1) receptor expressed on intratumoral T cells and provide an inhibitory signal, thereby suppressing the antitumor immune response. Monoclonal antibodies that block PD-1 signaling prevent T-cell inhibition and promote a T-cell–mediated antilymphoma response. Blocking antibodies that are directed against PD-1 or PD-L1 are currently being tested in patients with lymphoma and have shown remarkable efficacy, particularly in patients with relapsed Hodgkin lymphoma. On the basis of the prom...
📖 Papers frequently viewed together
11 Citations
12 Citations
38 Citations
#1Stephen M. Ansell (Mayo Clinic)H-Index: 99
#2Alexander M. Lesokhin (Cornell University)H-Index: 29
Last. Philippe Armand (Johns Hopkins University)H-Index: 76
view all 19 authors...
BACKGROUND Preclinical studies suggest that Reed–Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin’s lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling. We hypothesized that nivolumab, a PD-1–blocking antibody, could inhibit tumor immune evasion in patients with relap...
2,403 CitationsSource
#1Craig H. Moskowitz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 63
#2Vincent Ribrag (Institut Gustave Roussy)H-Index: 56
Last. Philippe Armand (Harvard University)H-Index: 76
view all 17 authors...
The programmed death-1 (PD-1) pathway serves as an immune checkpoint to temporarily dampen immune responses upon chronic antigen stimulation. Normal antigen presenting cells and certain tumor cells express the PD-1 ligands, PD-L1 and PD-L2, which engage PD-1 receptors on activated T cells and induce T-cell exhaustion. PD-1 signaling is a potent mechanism of tumor immune escape and a compelling target for therapy. Antibody-mediated PD-1 blockade has already been successfully exploited as a therap...
132 CitationsSource
#1Alexander M. Lesokhin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 29
#2Stephen M. Ansell (Mayo Clinic)H-Index: 99
Last. John M. Timmerman (UCLA: University of California, Los Angeles)H-Index: 41
view all 22 authors...
Introduction Programmed cell death-1 (PD-1) is an immune checkpoint receptor that inhibits T cell activation upon interaction with its ligands PD-L1 or PD-L2 . Increased PD-L1 expression has been reported in various lymphoid malignancies, and may allow these tumors to circumvent host anti-tumor immunity. Nivolumab, a fully human IgG4 monoclonal PD-1 receptor blocking antibody, potentiates T cell activity, and has clinical efficacy in various solid tumors. We hypothesized that nivolumab might als...
105 CitationsSource
#1Jacob P. Smeltzer (Mayo Clinic)H-Index: 3
#2Jason M. Jones (Mayo Clinic)H-Index: 6
Last. Stephen M. Ansell (Mayo Clinic)H-Index: 99
view all 12 authors...
Purpose: Transformation of follicular lymphoma is a critical event associated with a poor prognosis. The role of the tumor microenvironment in previous transformation studies has yielded conflicting results. Experimental Design: To define cell subtypes associated with transformation, we examined tissue specimens at diagnosis from patients with follicular lymphoma that later transformed and, using immunohistochemistry (IHC), stained for CD68, CD11c, CD21, CXCL13, FOXP3, PD1, and CD14. Cell conten...
67 CitationsSource
#1Zhi-Zhang Yang (Mayo Clinic)H-Index: 7
#2Deanna M. Grote (Mayo Clinic)H-Index: 18
Last. Stephen M. Ansell (Mayo Clinic)H-Index: 99
view all 9 authors...
TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin’s lymphoma
70 CitationsSource
#1Jason R. Westin (University of Texas MD Anderson Cancer Center)H-Index: 32
#2Fuliang Chu (University of Texas MD Anderson Cancer Center)H-Index: 17
Last. Sattva S. Neelapu (University of Texas MD Anderson Cancer Center)H-Index: 62
view all 22 authors...
Summary Background Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints might include effects of programmed cell death 1 (PD1), a co-inhibitory receptor that impairs T-cell function and is highly expressed on intratumoral T cells. We did this phase 2 trial to investigate the activity of pidilizumab, a humanised anti-PD1 monoclonal antibody, with rituximab...
431 CitationsSource
#1Philippe Armand (Harvard University)H-Index: 76
#2Arnon Nagler (Sheba Medical Center)H-Index: 118
Last. Leo I. Gordon (NU: Northwestern University)H-Index: 85
view all 24 authors...
Purpose The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance. The reconstituting immune landscape after autologous hematopoietic stem-cell transplantation (AHSCT) may be particularly favorable for breaking immune tolerance through PD-1 blockade. Patients and Methods We conducted an international phase II study of pidilizumab, an anti–PD-1 monoclonal antibody, in patients with DLBCL undergoi...
362 CitationsSource
#1Paul Greaves (QMUL: Queen Mary University of London)H-Index: 9
#2Andrew Clear (QMUL: Queen Mary University of London)H-Index: 27
Last. John G. Gribben (QMUL: Queen Mary University of London)H-Index: 117
view all 9 authors...
CD4+ T-helper cells (THs) dominate the classical Hodgkin lymphoma (CHL) microenvironment, but their role is poorly understood. Advances in flow cytometry and immunohistochemistry permit more detailed investigation of this aspect of CHL pathophysiology. To address the hypothesis that the TH-
110 CitationsSource
#1Zhi Zhang Yang (Mayo Clinic)H-Index: 17
#2Deanna M. Grote (Mayo Clinic)H-Index: 18
Last. Stephen M. Ansell (Mayo Clinic)H-Index: 99
view all 10 authors...
While the effect of TGF-β on malignant B cells in non-Hodgkin lymphoma (NHL) has been previously evaluated, studies to specifically define the role of TGF-β in tumor immunity in B-cell NHL are limited. We found that soluble TGF-β, secreted by both lymphoma cells and intratumoral T cells, is present in the serum of patients with B-cell NHL. Soluble TGF-β promoted regulatory T (Treg) cells by enhancing expression of Foxp3 in CD4+ T cells and suppressed effector helper T (TH) cells by inhibiting ex...
43 CitationsSource
#2J. Le Priol (French Institute of Health and Medical Research)H-Index: 2
Last. Karin TarteH-Index: 58
view all 13 authors...
Accumulating evidences indicate that the cellular and molecular microenvironment of follicular lymphoma (FL) has a key role in both lymphomagenesis and patient outcome. Malignant FL B cells are found admixed to specific stromal and immune cell subsets, in particular CD4(pos) T cells displaying phenotypic features of follicular helper T cells (T(FH)). The goal of our study was to functionally characterize intratumoral CD4(pos) T cells. We showed that CXCR5(hi)ICOS(hi)CD4(pos) T cells sorted from ...
123 CitationsSource
Cited By9
#1Xuewen Zhang (SYSU: Sun Yat-sen University)H-Index: 9
#2Xiwen Bi (SYSU: Sun Yat-sen University)H-Index: 7
Last. Wei-an Zeng (SYSU: Sun Yat-sen University)H-Index: 1
view all 10 authors...
Background: Natural killer/T-cell lymphoma (NKTCL) is a highly aggressive lymphoma with a dismal prognosis, and novel therapeutic targets are urgently needed. Programmed death-ligand 1 (PD-L1) has become a promising therapeutic target for various cancers, but most of the studies have focused on expression of PD-L1 on tumor cells. Expression of PD-L1 on tumor-infiltrating nonmalignant cells, especially monocytes, has not been studied in NKTCL, and its prognostic value remains unknown. Materials a...
4 CitationsSource
#1Saurabh Zanwar (Mayo Clinic)H-Index: 8
#2Stephen M. Ansell (Mayo Clinic)H-Index: 99
The tumor microenvironment (TME) constitutes a host of immune regulatory cells and their mediators that influence the intricate balance between the antitumor immunity and the intratumoral immune su...
#1Lili Guo (Zhengzhou University)H-Index: 17
#2Gang‑Cheng Wang (Zhengzhou University)
Last. Lin‑Bo Liu (Zhengzhou University)
view all 5 authors...
: Viral vectors represent a potential strategy for the treatment of human malignant tumors. Currently, recombinant adenovirus vectors are commonly used as gene therapy vehicles, as it possesses a proven safety profile in normal human cells. The recombinant adenovirus system has an ability to highly express exogenous genes and increase the stability of the carrier, which is only transiently expressed in the host cell genome, without integrating. Malignant melanoma cells are produced by the skin, ...
#1Adam Lynch (Longwood University)H-Index: 1
#2William Hawk (Longwood University)H-Index: 1
Last. Amorette Barber (Longwood University)H-Index: 5
view all 6 authors...
Summary Adoptive transfer of T cells is a promising cancer therapy and expression of chimeric antigen receptors can enhance tumor recognition and T cell effector functions. The PD1 receptor is a prospective target for a chimeric antigen receptor because PD1 ligands are expressed on many cancer types, including lymphoma. Therefore, we developed a murine chimeric PD1 receptor (chPD1) consisting of the PD1 extracellular domain fused to the cytoplasmic domain of CD3 zeta. Additionally, chimeric anti...
17 CitationsSource
#1Jose D. Sandoval-Sus (USF: University of South Florida)H-Index: 4
#2Francis Mogollon-Duffo (USF: University of South Florida)H-Index: 1
Last. Michael V. Jagal (USF: University of South Florida)H-Index: 1
view all 7 authors...
Background We report the first case to our knowledge of a patient with relapsed/refractory classical hodgkin lymphoma and liver failure with encephalopathy along with human immunodeficiency virus/acquired immunodeficiency syndrome infection, successfully treated with nivolumab without major side effects and encouraging prolonged disease control.
20 CitationsSource
Abstract Immune checkpoints inhibitors have been incorporated into standard treatment protocols for advanced solid tumors. The aim of T-cell-based immune therapy in cancer has been to generate durable clinical benefits for patients, paired with enhanced side effect profiles. The beneficial antitumoral activity of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has been thoroughly demonstrated in certain metastatic malignancies (e.g. melanoma, non-small cell lung cancer, renal cel...
18 CitationsSource
#1Natalie Galanina (UCSD: University of California, San Diego)H-Index: 10
#2Justin Kline (U of C: University of Chicago)H-Index: 31
Last. Michael R. Bishop (U of C: University of Chicago)H-Index: 57
view all 3 authors...
Following the successful application of immune checkpoint blockade therapy (CBT) in refractory solid tumors, it has recently gained momentum as a promising modality in the treatment of relapsed lymphoma. This significant therapeutic advance stems from decades of research that elucidated the role of immune regulation pathways and the mechanisms by which tumors can engage these critical pathways to escape immune detection. To date, two main pathways, the cytotoxic T-lymphocyte-associated protein 4...
17 CitationsSource
#1Stephanie Gaillard (Durham University)H-Index: 19
#2Angeles Alvarez Secord (Durham University)H-Index: 59
Last. Bradley J. Monk (UA: University of Arizona)H-Index: 51
view all 3 authors...
The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical efficacy of these agents in ovarian cancer with objective response rates of 10–15% with some durable responses. In this review, we present emerging clinical data of completed trials of immune checkpoint inhibitors and review ongoing studies. In addition we examine the current knowledge of the ...
90 CitationsSource
#1Joseph M. Connors (UBC: University of British Columbia)H-Index: 108
1 CitationsSource